HER2/neu protein overexpression, assessed by immunohistochemistry (IHC), has been associated with increased tumour grade in TCC, but there is a wide variation in the literature of 2–50% (Wright et al, 1990; Coombs et al, 1991; McCann et al, 1990; Underwood et al, 1995; Mellon et al, 1996). Here, ERBB2 is linked to neoplasm.